FDA OK's fluoroquinolone Avelox for plague
This article was originally published in Scrip
Executive Summary
The FDA on 8 May gave its blessing to Merck to market Avelox (moxifloxacin), a fluoroquinolone antibacterial, as a treatment for plague, including pneumonic plague, which is a bacterial infection of the lungs, and septicemic plague, and infection of the blood.